The new owner, Regeneron Pharmaceuticals intends to continue providing 23andMe’s consumer genome services, it said.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Pharmaceutical giant Regeneron has promised to prioritise the “ethical use” of the sequenced DNA data of more than 15 million ...

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

Wall Street indices closed mixed on Monday. Moody's downgraded the U.S. credit rating due to rising debt. S&P 500 marked its ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Scott Adams, the creator of the "Dilbert" comic strip, revealed Monday he is battling the same metastatic prostate cancer as ...

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...